世界の薬物遺伝子検査市場
Market Size in USD Billion
CAGR :
% 
 予測期間 |
2024 –2030 |
 市場規模（基準年） |
|
 Market Size (Forecast Year) |
USD 11,442.40 |
 CAGR |
% |
| 主要市場プレーヤー |
>世界の薬理遺伝子検査市場、タイプ別（全ゲノムシーケンシング、全エクソームシーケンシング、アレイベース検査、単一遺伝子検査）、遺伝子タイプ別（CYP2C19、CYP2D6、CYP2C9およびVKORC1、CYP1A2、HLA-B*1502、HLA-B*5701、CYP2D、OPRM1、ONCOTYPE DXおよびMAMMAPRINT、DRD3、D4D4、SLC6A4、HTR2A/C、TMPT、その他）、薬剤タイプ別（処方薬、栄養補助食品、娯楽用医薬品、ハーブサプリメント、ビタミン、市販薬）、サンプル別（血液および唾液）、治療領域別（心臓病学、消化器病学、麻酔学、ゲノミクス、内分泌学免疫学、医療（アレルギー、過敏症、皮膚科、婦人科、腫瘍学、神経学、その他）、アプリケーション（臨床診療、医薬品開発、医薬品規制）、エンドユーザー（医療提供者、製薬およびバイオテクノロジー企業、研究センターおよび学術機関、その他）、流通チャネル（病院薬局、小売薬局、通信販売薬局、顧客直販サービス） - 2030 年までの業界動向と予測。
薬物遺伝子検査市場の分析と規模
世界の薬物遺伝子検査市場は、2023年から2030年の予測期間に市場成長を遂げると予想されています。市場は、薬物遺伝子検査市場を必要とする市場である個別化医療の採用増加によって推進されています。
電子健康記録（EHR）の統合は、市場の成長の重要な原動力です。慢性疾患や複雑な疾患の増加により、市場の成長機会が生まれると予想されています。データブリッジマーケットリサーチは、市場は2023年から2030年の予測期間に8.7％のCAGRで成長し、2030年までに114億4,240万米ドルに達すると分析しています。ゲノム技術の進歩が市場の拡大を牽引すると予想されています。
|
レポートメトリック |
詳細 |
|
予測期間 |
2023年から2030年 |
|
基準年 |
2022 |
|
歴史的な年 |
2021 (カスタマイズ可能 2015-2020) |
|
定量単位 |
収益（百万米ドル） |
|
対象セグメント |
タイプ（全ゲノムシーケンシング、全エクソームシーケンシング、アレイベーステスト、単一遺伝子テスト）、遺伝子タイプ（CYP2C19、CYP2D6、CYP2C9およびVKORC1、CYP1A2、HLA-B*1502、HLA-B*5701、CYP2D、OPRM1、ONCOTYPE DXおよびMAMMAPRINT、DRD3、D4D4、SLC6A4、HTR2A/C、TMPT、その他）、薬剤タイプ（処方薬、栄養補助食品、娯楽用医薬品、ハーブサプリメント、ビタミン、市販薬）、サンプル（血液および唾液）、治療領域（心臓病学、消化器病学、麻酔学、ゲノミクス、内分泌学、免疫学および過敏症、皮膚科、医療従事者（婦人科、腫瘍学、神経学、その他）、アプリケーション（臨床診療、医薬品開発、医薬品規制）、エンドユーザー（医療提供者、製薬・バイオテクノロジー企業、研究センターおよび学術機関、その他）、流通チャネル（病院薬局、小売薬局、通信販売薬局、顧客直販サービス） |
|
対象国 |
米国、カナダ、メキシコ、フランス、ドイツ、スペイン、イタリア、英国、スペイン、オランダ、ロシア、トルコ、スイス、その他のヨーロッパ諸国、中国、日本、タイ、インド、韓国、オーストラリア、シンガポール、インドネシア、フィリピン、マレーシア、その他のアジア太平洋諸国、ブラジル、アルゼンチン、その他の南米諸国、UAE、サウジアラビア、南アフリカ、イスラエル、エジプト、その他の中東およびアフリカ諸国 |
|
対象となる市場プレーヤー |
PerkinElmer Inc.、Illumina, Inc.、Thermo Fisher Scientific Inc.、Dynamic DNA Laboratories、Sonic Healthcare、QIAGEN、Eurofins Scientific、23andMe, Inc、OneOme、BGI、PacBio、MD Labs、GENEWIZ、PGXT、Luminex Corporation、Myriad Genetics, Inc. など |
薬理遺伝子検査市場の定義
薬理遺伝子検査には、個人の遺伝子プロファイルを検査して、個人の遺伝子が特定の薬に対する反応にどのように影響するかを突き止めるサービスが含まれます。この特殊な遺伝子検査では、さまざまな薬の代謝、有効性、および潜在的な副作用に影響を与える可能性のある特定の遺伝子変異を特定します。医療専門家は、患者に合わせて薬の選択と投与量をカスタマイズして、治療結果を改善し、副作用を減らし、全体的な薬効を高めることができます。これは、患者の遺伝的素因を認識することによって行われます。このパーソナライズされた薬の選択と投与量のアプローチにより、医療の質と患者の結果が向上する可能性があります。
薬理遺伝子検査市場の動向
このセクションでは、市場の推進要因、利点、機会、制約、課題について理解します。これらについては、以下で詳しく説明します。
ドライバー
- 個別化医療の導入拡大
薬理遺伝子検査は、個人の遺伝子構成に合わせて薬物治療を調整することで、個別化医療において重要な役割を果たします。この革新的なアプローチでは、個人の遺伝子変異を分析します。遺伝子変異は、特定の薬剤の代謝や反応に影響を与える可能性があります。これらの遺伝子の違いは薬剤の有効性や潜在的な副作用に影響を与える可能性があるため、薬理遺伝子検査は個別化治療計画にとって貴重なツールとなります。
医療従事者は、個人の固有の遺伝子プロファイルを調べることで、身体が薬物を処理および利用する方法を決定づける遺伝子マーカーを特定できます。この情報により、薬物の選択と投与量をカスタマイズして、治療結果を最適化することができます。たとえば、一部の個人は、特定の薬物に対してより敏感になる遺伝子変異を持っている場合があり、副作用なしに望ましい治療効果を得るためには、より低い投与量が必要になります。一方、一部の遺伝子変異では、同じ効果を得るためにより高い投与量が必要になる場合があります。このカスタマイズされたアプローチにより、薬物の選択に伴う「試行錯誤」が最小限に抑えられ、副作用のリスクが軽減され、治療効果が向上します。これにより、医療従事者は情報に基づいた決定を下し、患者の遺伝的素因に基づいて、患者によく効く可能性のある薬物を処方できるようになります。最終的に、薬理遺伝子検査は、パーソナライズ医療のパラダイムに大きく貢献し、より正確で個別化された治療戦略を促進して患者の転帰を改善することで、医療に革命をもたらします。
したがって、市場はこの需要の急増の恩恵を受けており、より包括的で正確な検査ソリューションを作成するための研究開発活動が一貫して増加しています。次世代シーケンシング（NGS）やその他の分子診断技術などの技術の進歩により、これらの検査の精度と手頃な価格がさらに向上しています。その結果、パーソナライズ医療の台頭と市場の繁栄の間に相互に強化する関係が生まれ、どちらも医療環境に大きな影響を与え、治療がカスタマイズされ、効果的で、患者中心になる未来を約束し、市場の成長を促進すると予想されています。
- ゲノム技術の進歩
ゲノム技術革新の継続的な急増により、遺伝子検査の精度、速度、コスト効率が大幅に向上しました。次世代シーケンシング (NGS) やその他の最先端の分子診断技術は、極めて重要なツールとして登場し、遺伝情報の分析と解釈の方法に革命をもたらしました。これらの高度なゲノム技術の統合により、薬理遺伝子検査の精度と範囲が強化され、個人の遺伝子プロファイルの包括的な評価が可能になりました。これにより、医療専門家は、患者固有の遺伝子構成に合わせた薬剤の選択、投与、治療戦略について十分な情報に基づいた決定を下すことができます。
さらに、CRISPR-Cas9 遺伝子編集技術は、特定の遺伝子変異の機能的影響の研究において有望であることが示されています。この技術により、研究者は遺伝子を正確に変更し、特定の遺伝子変異を模倣し、薬物代謝と反応への影響を解明することができます。これらの進歩は、市場の洗練と拡大に総合的に貢献し、独自の遺伝子設計図に基づいて各個人に合わせた医薬品が提供される未来に近づき、市場の成長を促進すると予想されます。
機会
- 電子健康記録（EHR）との統合
シームレスな統合により、包括的な患者の健康記録とともに、効率的で一元化された遺伝子データの保存が可能になります。この融合により、医療専門家の薬理遺伝学的情報のアクセス性と使いやすさが向上し、リアルタイムでデータに基づいた意思決定が可能になります。医師は治療計画中に遺伝学的洞察に容易にアクセスでき、患者固有の遺伝子構成に合った薬の処方を確実に行うことができます。この統合によって達成される効率性の向上により、薬理遺伝学的検査の採用が加速され、患者ケアの改善、ワークフローの合理化、そして最終的には市場の成長の促進に貢献します。
さらに、EHR との統合により、より広範囲にわたる研究とデータ分析が容易になります。EHR 内の集約され匿名化された遺伝子データは、研究や臨床研究に活用でき、薬理ゲノミクスの進歩を促進します。製薬会社、研究機関、医療提供者は、このデータを活用して、医薬品開発を強化し、遺伝子の関連性を検証し、治療戦略を最適化できます。市場と EHR のこのコラボレーションは、イノベーションを促進します。これにより、医療分野に利益をもたらし、強化された研究、製品開発、データ主導の意思決定を通じて市場を前進させる相乗的なエコシステムが促進され、市場の成長機会が生まれることが期待されます。
抑制/挑戦
- 結果の解釈における医療およびゲノムの専門家への依存
市場は、結果の解釈を医療およびゲノムの専門家に大きく依存するという顕著な制約に直面しています。遺伝子データは複雑な性質を持っているため、正確で意味のある理解には専門知識と専門技術が必要です。薬理遺伝子検査の結果を正しく解釈するには、遺伝学者、薬理学者、ゲノムの専門家など、高度なスキルを持つ専門家に大きく依存します。この依存性は、薬理遺伝子検査の拡張性と広範な採用の点で課題をもたらします。資格のある専門家の数が限られており、正確な解釈に必要な時間と労力により、医療従事者や患者に実用的な洞察を提供することが遅れることがよくあります。さらに、専門家への依存はコストとリソースの利用の増加につながり、薬理遺伝子検査を日常の臨床診療にシームレスに統合することを妨げる可能性があります。この制約を克服するには、自動化されたデータ分析ツール、ユーザーフレンドリーなインターフェース、包括的な教育プログラムの進歩が必要であり、より幅広い医療専門家が薬理遺伝子検査の結果を正確に解釈して活用できるようにする必要があります。したがって、この市場は、個人の遺伝子構成に基づいて薬物療法をカスタマイズする上で大きな可能性を秘めています。重大な課題は、検査結果の解釈を医療およびゲノムの専門家に依存していることです。遺伝子データの複雑さには特定の専門知識が必要であり、結果を解釈して臨床上の決定を下すことが困難であり、これが市場の成長を抑制すると予想されます。
最近の開発
- 2023年5月、パーキンエルマー社は、診断とライフサイエンスの進歩を利用して世界中の人々の生活を向上させる科学ベースのソリューションを提供する企業として、Revvity, Inc.の設立を発表しました。以前は、この事業はパーキンエルマー社と提携していました。Revvityの顧客は、製薬およびバイオテクノロジー、診断ラボ、学術機関、政府機関など、さまざまな業界に及びます。Revvityは、試薬、消耗品、アッセイ、機器、ソフトウェアを提供しています。
- 2022年10月、PacBioとTwist Bioscience Corporationは、既製のロングリード遺伝子パネルの初期ポートフォリオの提供を発表しました。これらの固定Twist Allianceパネルは、ターゲット領域を効率的かつコスト効率よくキャプチャするように作られています。さらに、顧客はPacBio HiFiリードを使用して、シーケンスに完全に適応し、拡張可能な独自のデザインのパネルを作成することができます。
世界の薬物遺伝子検査市場の範囲
世界の薬物遺伝子検査市場は、タイプ、遺伝子タイプ、薬物タイプ、サンプル、治療領域、アプリケーション、エンドユーザー、流通チャネルに基づいて、8つの主要なセグメントに分割されています。これらのセグメントの成長は、業界の主要な成長セグメントを分析し、ユーザーに貴重な市場概要と市場洞察を提供し、コア市場アプリケーションを特定するための戦略的決定を下すのに役立ちます。
タイプ
- 全ゲノム配列解析
- 全エクソーム配列解析
- 配列ベースのテスト
- 単一遺伝子検査
タイプに基づいて、市場は全ゲノム配列解析、全エクソーム配列解析、アレイベースのテスト、および単一遺伝子テストに分類されます。
遺伝子型
- CYP2C19
- CYP2D6
- CYP2C9とVKORC1
- CYP1A2
- HLA-B*1502
- HLA-B*5701
- CYP2D
- OPRM1
- ONCOTYPE DX® と MAMMAPRINT®
- DRD3
- D4D4
- SLC6A4
- HTR2A/C
- TMPT
- その他
遺伝子タイプに基づいて、市場は CYP2C19、CYP2D6、CYP2C9 および VKORC1、CYP1A2、HLA-B*1502、HLA-B*5701、CYP2D、OPRM1、ONCOTYPE DX および MAMMAPRINT、DRD3、D4D4、SLC6A4、HTR2A/C、TMPT などに分類されます。
薬剤の種類
医薬品の種類に基づいて、市場は処方薬、栄養補助食品、娯楽用医薬品、ハーブサプリメント、ビタミン、市販薬に分類されます。
サンプル
- 血
- 唾液
サンプルに基づいて、市場は血液と唾液に分類されます。
治療領域
- 心臓病学
- 消化器内科
- 麻酔科
- ゲノミクス
- 内分泌学
- 免疫学と過敏症
- 皮膚科
- 婦人科
- 腫瘍学
- 神経学
- その他
治療領域に基づいて、市場は心臓病学、消化器病学、麻酔学、ゲノム科学、内分泌学、免疫学および過敏症、皮膚科、婦人科、腫瘍学、神経学、その他に分類されます。
応用
- 臨床実践
- 医薬品開発
- 薬物規制
アプリケーションに基づいて、市場は臨床実践、医薬品開発、医薬品規制に分類されます。
エンドユーザー
- 医療提供者
- 製薬・バイオテクノロジー企業
- センターおよび学術機関
- その他
エンドユーザーに基づいて、市場はヘルスケア提供者、製薬およびバイオテクノロジー企業、研究センターおよび学術機関、その他に分類されます。
流通チャネル
- 病院薬局
- 小売薬局
- 通信販売薬局
- 顧客直結サービス
流通チャネルに基づいて、市場は病院薬局、小売薬局、通信販売薬局、および顧客直接サービスに分類されます。
地域分析/洞察: 薬物遺伝子検査市場
世界の薬物遺伝子検査市場が分析され、上記のタイプ、遺伝子タイプ、薬物タイプ、サンプル、治療領域、アプリケーション、エンドユーザー、流通チャネルに基づいて市場規模の洞察と傾向が提供されます。
市場レポートで取り上げられている国は、米国、カナダ、メキシコ、フランス、ドイツ、スペイン、イタリア、英国、スペイン、オランダ、ロシア、トルコ、スイス、その他のヨーロッパ諸国、中国、日本、タイ、インド、韓国、オーストラリア、シンガポール、インドネシア、フィリピン、マレーシア、その他のアジア太平洋諸国、ブラジル、アルゼンチン、その他の南米諸国、UAE、サウジアラビア、南アフリカ、イスラエル、エジプト、その他の中東およびアフリカ諸国です。
米国は、その先進的なインフラと、質の高い医療インフラセンターの広範なネットワークにより、北米地域を支配すると予想されています。ドイツは、バイオテクノロジーと医療に関連する研究開発の増加により、ヨーロッパ地域を支配すると予想されています。日本は、薬物遺伝子検査市場に関する需要の増加と認識の高まりにより、アジア太平洋地域を支配すると予想されています。
レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える個別の市場影響要因と市場規制の変更も提供しています。下流および上流のバリュー チェーン分析、技術動向、ポーターの 5 つの力の分析、ケース スタディなどのデータ ポイントは、個々の国の市場シナリオを予測するために使用される指標の一部です。また、国別データの予測分析を提供する際には、地域ブランドの存在と可用性、地元および国内ブランドとの競争が激しいか少ないために直面する課題、国内関税と貿易ルートの影響も考慮されます。
薬物遺伝子検査市場の競争環境とシェア分析
世界の薬物遺伝子検査市場の競争状況は、競合他社ごとに詳細を提供します。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、地域的プレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性が含まれます。提供されている上記のデータ ポイントは、市場に対する会社の重点にのみ関連しています。
世界の薬物遺伝子検査市場で活動している主要企業としては、PerkinElmer Inc.、Illumina, Inc.、Thermo Fisher Scientific Inc.、Dynamic DNA Laboratories、Sonic Healthcare、QIAGEN、Eurofins Scientific、23andMe, Inc、OneOme、BGI、PacBio、MD Labs、GENEWIZ、PGXT、Luminex Corporation、Myriad Genetics, Inc. などが挙げられます。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL PHARMACOGENETIC TESTING MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 DBMR MARKET POSITION GRID
2.7 MULTIVARIATE MODELLING
2.8 TYPE LIFELINE CURVE
2.9 MARKET END USER COVERAGE GRID
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’SFIVE FORCES
4.3 INDUSTRY INSIGHTS AND STRATEGIC ANALYSIS
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 INCREASING ADOPTION OF PERSONALIZED MEDICINE
5.1.2 ADVANCEMENTS IN GENOMIC TECHNOLOGIES
5.1.3 INCREASING CHRONIC AND COMPLEX DISEASES
5.1.4 ROLE OF PHARMACOGENETIC TESTING IN DRUG DISCOVERY AND DEVELOPMENT
5.2 RESTRAINTS
5.2.1 DEPENDENCY ON THE MEDICAL AND GENOMIC EXPERT FOR RESULT INTERPRETATION
5.2.2 ETHICAL AND PRIVACY CONCERNS ASSOCIATED WITH PHARMACOGENETIC TESTING
5.3 OPPORTUNITIES
5.3.1 INTEGRATION WITH ELECTRONIC HEALTH RECORDS (EHRS)
5.3.2 ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING INTEGRATION IN HEALTHCARE
5.4 CHALLENGES
5.4.1 CHALLENGES IN CLINICAL IMPLEMENTATION OF PHARMACOGENETICS
5.4.2 COMPLEXITY ASSOCIATED WITH PHARMACOGENETIC TESTING RESULTS
6 GLOBAL PHARMACOGENETIC TESTING MARKET, BY TYPE
6.1 OVERVIEW
6.2 WHOLE GENOME SEQUENCING
6.2.1 NEXT GENERATION SEQUENCING (NGS)
6.2.2 SANGER SEQUENCING
6.3 WHOLE EXOME SEQUENCING
6.3.1 NEXT GENERATION SEQUENCING (NGS)
6.3.2 SANGER SEQUENCING
6.4 ARRAY-BASED TESTS
6.4.1 GLASS SLIDE ARRAYS
6.4.2 IN—SITU SYNTHESIZED ARRAYS
6.4.3 SELF ASSEMBLED ARRAYS
6.5 SINGLE GENE TESTS
6.5.1 NEXT GENERATION SEQUENCING (NGS)
6.5.2 SANGER SEQUENCING
7 GLOBAL PHARMACOGENETIC TESTING MARKET, BY GENE TYPE
7.1 OVERVIEW
7.2 CYP2C19
7.3 CYP2D6
7.4 CYP2C9 AND VKORC1
7.5 CYP1A2
7.6 HLA-B*1502
7.7 HLA-B*5701
7.8 CYP2D
7.9 OPRM1
7.1 ONCOTYPE DX* AND MAMMAPRINT
7.11 DRD3
7.12 D4D4
7.13 SLC6A4
7.14 HTR2A/C
7.15 TMPT
7.16 OTHERS
8 GLOBAL PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE
8.1 OVERVIEW
8.2 PRESCRIPTION DRUGS
8.3 NUTRACEUTICALS
8.4 RECREATIONAL DRUGS
8.5 HERBAL SUPPLEMENTS
8.6 VITAMINS
8.7 OVER-THE-COUNTER MEDICATIONS
9 GLOBAL PHARMACOGENETIC TESTING MARKET, BY SAMPLE
9.1 OVERVIEW
9.2 BLOOD
9.3 SALIVA
10 GLOBAL PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA
10.1 OVERVIEW
10.2 CARDIOLOGY
10.3 GASTROENTEROLOGY
10.4 ANESTHESIOLOGY
10.5 GENOMICS
10.6 ENDOCRINOLOGY
10.7 IMMUNOLOGY & HYPERSENSITIVITY
10.8 DERMATOLOGY
10.9 GYNECOLOGY
10.1 ONCOLOGY
10.11 NEUROLOGY
10.12 OTHERS
11 GLOBAL PHARMACOGENETIC TESTING MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 CLINICAL PRACTICE
11.2.1 SIDE EFFECTS
11.2.2 DRUG EFFECTIVENESS
11.2.3 DOSAGE
11.3 DRUG DEVELOPMENT
11.3.1 DRUG EFFECTIVENESS
11.3.2 DOSAGE
11.3.3 SIDE EFFECTS
11.4 DRUG REGULATION
11.4.1 SIDE EFFECTS
11.4.2 DRUG EFFECTIVENESS
11.4.3 DOSAGE
12 GLOBAL PHARMACOGENETIC TESTING MARKET, BY END USER
12.1 OVERVIEW
12.2 HEALTHCARE PROVIDERS
12.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
12.4 RESEARCH CENTRES AND ACADEMIC INSTITUTES
12.5 OTHERS
13 GLOBAL PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 HOSPITAL PHARMACY
13.3 RETAIL PHARMACIES
13.4 MAIL-ORDER PHARMACIES
13.5 DIRECT-TO-CUSTOMER SERVICES
14 GLOBAL PHARMACOGENETIC TESTING MARKET, BY REGION
14.1 OVERVIEW
14.2 NORTH AMERICA
14.3 EUROPE
14.4 ASIA-PACIFIC
14.5 SOUTH AMERICA
14.6 MIDDLE EAST AND AFRICA
15 GLOBAL PHARMACOGENETIC TESTING MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: GLOBAL
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
15.3 COMPANY SHARE ANALYSIS: EUROPE
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 THERMO FISHER SCIENTIFIC INC.
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENTS
17.2 ILLUMINA, INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.3 QIAGEN
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENT
17.4 SONIC HEALTHCARE
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 BGI
17.5.1 COMPANY SNAPSHOT
17.5.2 COMPANY SHARE ANALYSIS
17.5.3 PRODUCT PORTFOLIO
17.5.4 RECENT DEVELOPMENT
17.6 23ANDME, INC
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.7 DYNAMIC DNA LABORATORIES
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT DEVELOPMENT
17.8 EUROFINS SCIENTIFIC (2022)
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENT
17.9 GENEWIX (A SUBSIDIARY OF AZENTA LIFE SCIENCE)
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.1 LUMINEX CORPORATION (A SUBSIDIARY OF DIASORIN)
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 RECENT DEVELOPMENT
17.11 MD LABS
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 RECENT DEVELOPMENT
17.12 MYRIAD GENETICS, INC.
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENTS
17.13 ONEOME
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENT
17.14 PACBIO
17.14.1 COMPANY SNAPSHOT
17.14.2 REVENUE ANALYSIS
17.14.3 PRODUCT PORTFOLIO
17.14.4 RECENT DEVELOPMENT
17.15 PERKINELMER INC.
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENT
17.16 PGXT
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
表のリスト
TABLE 1 GLOBAL PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 2 GLOBAL WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 GLOBAL WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 4 GLOBAL WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 5 GLOBAL WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 6 GLOBAL ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 7 GLOBAL ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 8 GLOBAL SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 9 GLOBAL SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 10 GLOBAL PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 11 GLOBAL CYP2C19 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 GLOBAL CYP2D6 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 GLOBAL CYP2C9 AND VKORC1 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 GLOBAL CYP1A2 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 GLOBAL HLA-B*1502 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 GLOBAL HLA-B*5701 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 GLOBAL CYP2D IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 GLOBAL OPRM1 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 GLOBAL ONCOTYPE DX* AND MAMMAPRINT IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 GLOBAL DRD3 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 GLOBAL D4D4 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 GLOBAL SLC6A4 IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 GLOBAL HTR2A/C IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 GLOBAL TMPT IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 GLOBAL OTHERS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 GLOBAL PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 27 GLOBAL PRESCRIPTION DRUGS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 GLOBAL NUTRACEUTICALS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 GLOBAL RECREATIONAL DRUGS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 GLOBAL HERBAL SUPPLEMENTS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 GLOBAL VITAMINS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 GLOBAL OVER-THE-COUNTER MEDICATIONS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 GLOBAL PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 34 GLOBAL BLOOD IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 GLOBAL SALIVA IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 36 GLOBAL PHARMACOGENETIC TESTING MARKET, BY THERPAEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 37 GLOBAL CARDIOLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 GLOBAL GASTROENTEROLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 39 GLOBAL ANESTHESIOLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 GLOBAL GENOMICS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 41 GLOBAL ENDOCRINOLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 GLOBAL IMMUNOLOGY & HYPERSENSITIVITY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 GLOBAL DERMATOLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 GLOBAL GYNECOLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 45 GLOBAL ONCOLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 GLOBAL NEUROLOGY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 GLOBAL OTHERS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 GLOBAL PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 49 GLOBAL CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 GLOBAL CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 51 GLOBAL DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 52 GLOBAL DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 53 GLOBAL DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 54 GLOBAL DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 55 GLOBAL PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 56 GLOBAL HEALTHCARE PROVIDERS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 57 GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 58 GLOBAL RESEARCH CENTRES AND ACADEMIC INSTITUTES IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 59 GLOBAL OTHERS IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 60 GLOBAL PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)
TABLE 61 GLOBAL HOSPITAL PHARMACY IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 62 GLOBAL RETAIL PHARMACIES IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 63 GLOBAL MAIL-ORDER PHARMACIES IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 64 GLOBAL DIRECT-TO-CUSTOMER SERVICES IN PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 65 GLOBAL PHARMACOGENETIC TESTING MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 66 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 67 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 68 NORTH AMERICA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 69 NORTH AMERICA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 70 NORTH AMERICA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 71 NORTH AMERICA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 72 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 73 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 74 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 75 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 76 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 77 NORTH AMERICA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 78 NORTH AMERICA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 79 NORTH AMERICA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 80 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 81 NORTH AMERICA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 82 U.S. PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 83 U.S. WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 84 U.S. WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 85 U.S. ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 86 U.S. SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 87 U.S. PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 88 U.S. PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 89 U.S. PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 90 U.S. PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 91 U.S. PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 92 U.S. CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 93 U.S. DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 94 U.S. DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 95 U.S. PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 96 U.S. PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 97 CANADA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 98 CANADA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 99 CANADA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 100 CANADA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 101 CANADA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 102 CANADA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 103 CANADA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 104 CANADA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 105 CANADA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 106 CANADA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 107 CANADA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 108 CANADA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 109 CANADA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 110 CANADA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 111 CANADA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 112 MEXICO PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 113 MEXICO WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 114 MEXICO WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 115 MEXICO ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 116 MEXICO SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 117 MEXICO PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 118 MEXICO PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 119 MEXICO PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 120 MEXICO PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 121 MEXICO PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 122 MEXICO CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 123 MEXICO DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 124 MEXICO DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 125 MEXICO PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 126 MEXICO PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 127 EUROPE PHARMACOGENETIC TESTING MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 128 EUROPE PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 129 EUROPE WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 130 EUROPE WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 131 EUROPE ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 132 EUROPE SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 133 EUROPE PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 134 EUROPE PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 135 EUROPE PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 136 EUROPE PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 137 EUROPE PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 138 EUROPE CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 139 EUROPE DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 140 EUROPE DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 141 EUROPE PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 142 EUROPE PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 143 GERMANY PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 144 GERMANY WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 145 GERMANY WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 146 GERMANY ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 147 GERMANY SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 148 GERMANY PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 149 GERMANY PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 150 GERMANY PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 151 GERMANY PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 152 GERMANY PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 153 GERMANY CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 154 GERMANY DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 155 GERMANY DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 156 GERMANY PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 157 GERMANY PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 158 FRANCE PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 159 FRANCE WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 160 FRANCE WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 161 FRANCE ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 162 FRANCE SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 163 FRANCE PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 164 FRANCE PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 165 FRANCE PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 166 FRANCE PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 167 FRANCE PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 168 FRANCE CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 169 FRANCE DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 170 FRANCE DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 171 FRANCE PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 172 FRANCE PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 173 U.K. PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 174 U.K. WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 175 U.K. WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 176 U.K. ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 177 U.K. SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 178 U.K. PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 179 U.K. PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 180 U.K. PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 181 U.K. PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 182 U.K. PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 183 U.K. CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 184 U.K. DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 185 U.K. DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 186 U.K. PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 187 U.K. PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 188 ITALY PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 189 ITALY WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 190 ITALY WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 191 ITALY ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 192 ITALY SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 193 ITALY PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 194 ITALY PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 195 ITALY PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 196 ITALY PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 197 ITALY PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 198 ITALY CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 199 ITALY DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 200 ITALY DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 201 ITALY PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 202 ITALY PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 203 SPAIN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 204 SPAIN WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 205 SPAIN WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 206 SPAIN ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 207 SPAIN SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 208 SPAIN PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 209 SPAIN PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 210 SPAIN PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 211 SPAIN PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 212 SPAIN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 213 SPAIN CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 214 SPAIN DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 215 SPAIN DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 216 SPAIN PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 217 SPAIN PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 218 RUSSIA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 219 RUSSIA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 220 RUSSIA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 221 RUSSIA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 222 RUSSIA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 223 RUSSIA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 224 RUSSIA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 225 RUSSIA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 226 RUSSIA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 227 RUSSIA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 228 RUSSIA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 229 RUSSIA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 230 RUSSIA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 231 RUSSIA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 232 RUSSIA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 233 TURKEY PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 234 TURKEY WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 235 TURKEY WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 236 TURKEY ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 237 TURKEY SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 238 TURKEY PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 239 TURKEY PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 240 TURKEY PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 241 TURKEY PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 242 TURKEY PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 243 TURKEY CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 244 TURKEY DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 245 TURKEY DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 246 TURKEY PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 247 TURKEY PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 248 BELGIUM PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 249 BELGIUM WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 250 BELGIUM WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 251 BELGIUM ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 252 BELGIUM SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 253 BELGIUM PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 254 BELGIUM PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 255 BELGIUM PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 256 BELGIUM PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 257 BELGIUM PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 258 BELGIUM CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 259 BELGIUM DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 260 BELGIUM DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 261 BELGIUM PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 262 BELGIUM PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 263 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 264 NETHERLANDS WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 265 NETHERLANDS WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 266 NETHERLANDS ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 267 NETHERLANDS SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 268 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 269 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 270 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 271 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 272 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 273 NETHERLANDS CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 274 NETHERLANDS DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 275 NETHERLANDS DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 276 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 277 NETHERLANDS PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 278 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 279 SWITZERLAND WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 280 SWITZERLAND WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 281 SWITZERLAND ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 282 SWITZERLAND SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 283 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 284 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 285 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 286 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 287 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 288 SWITZERLAND CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 289 SWITZERLAND DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 290 SWITZERLAND DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 291 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 292 SWITZERLAND PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 293 REST OF EUROPE PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 294 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 295 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 296 ASIA-PACIFIC WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 297 ASIA-PACIFIC WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 298 ASIA-PACIFIC ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 299 ASIA-PACIFIC SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 300 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 301 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 302 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 303 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 304 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 305 ASIA-PACIFIC CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 306 ASIA-PACIFIC DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 307 ASIA-PACIFIC DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 308 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 309 ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 310 JAPAN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 311 JAPAN WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 312 JAPAN WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 313 JAPAN ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 314 JAPAN SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 315 JAPAN PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 316 JAPAN PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 317 JAPAN PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 318 JAPAN PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 319 JAPAN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 320 JAPAN CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 321 JAPAN DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 322 JAPAN DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 323 JAPAN PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 324 JAPAN PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 325 CHINA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 326 CHINA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 327 CHINA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 328 CHINA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 329 CHINA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 330 CHINA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 331 CHINA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 332 CHINA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 333 CHINA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 334 CHINA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 335 CHINA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 336 CHINA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 337 CHINA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 338 CHINA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 339 CHINA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 340 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 341 SOUTH KOREA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 342 SOUTH KOREA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 343 SOUTH KOREA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 344 SOUTH KOREA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 345 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 346 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 347 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 348 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 349 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 350 SOUTH KOREA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 351 SOUTH KOREA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 352 SOUTH KOREA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 353 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 354 SOUTH KOREA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 355 INDIA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 356 INDIA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 357 INDIA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 358 INDIA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 359 INDIA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 360 INDIA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 361 INDIA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 362 INDIA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 363 INDIA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 364 INDIA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 365 INDIA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 366 INDIA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 367 INDIA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 368 INDIA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 369 INDIA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 370 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 371 AUSTRALIA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 372 AUSTRALIA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 373 AUSTRALIA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 374 AUSTRALIA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 375 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 376 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 377 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 378 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 379 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 380 AUSTRALIA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 381 AUSTRALIA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 382 AUSTRALIA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 383 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 384 AUSTRALIA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 385 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 386 SINGAPORE WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 387 SINGAPORE WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 388 SINGAPORE ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 389 SINGAPORE SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 390 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 391 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 392 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 393 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 394 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 395 SINGAPORE CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 396 SINGAPORE DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 397 SINGAPORE DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 398 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 399 SINGAPORE PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 400 THAILAND PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 401 THAILAND WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 402 THAILAND WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 403 THAILAND ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 404 THAILAND SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 405 THAILAND PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 406 THAILAND PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 407 THAILAND PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 408 THAILAND PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 409 THAILAND PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 410 THAILAND CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 411 THAILAND DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 412 THAILAND DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 413 THAILAND PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 414 THAILAND PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 415 MALAYSIA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 416 MALAYSIA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 417 MALAYSIA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 418 MALAYSIA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 419 MALAYSIA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 420 MALAYSIA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 421 MALAYSIA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 422 MALAYSIA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 423 MALAYSIA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 424 MALAYSIA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 425 MALAYSIA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 426 MALAYSIA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 427 MALAYSIA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 428 MALAYSIA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 429 MALAYSIA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 430 INDONESIA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 431 INDONESIA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 432 INDONESIA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 433 INDONESIA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 434 INDONESIA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 435 INDONESIA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 436 INDONESIA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 437 INDONESIA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 438 INDONESIA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 439 INDONESIA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 440 INDONESIA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 441 INDONESIA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 442 INDONESIA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 443 INDONESIA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 444 INDONESIA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 445 PHILIPPINES PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 446 PHILIPPINES WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 447 PHILIPPINES WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 448 PHILIPPINES ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 449 PHILIPPINES SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 450 PHILIPPINES PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 451 PHILIPPINES PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 452 PHILIPPINES PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 453 PHILIPPINES PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 454 PHILIPPINES PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 455 PHILIPPINES CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 456 PHILIPPINES DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 457 PHILIPPINES DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 458 PHILIPPINES PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 459 PHILIPPINES PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 460 REST OF ASIA-PACIFIC PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 461 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 462 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 463 SOUTH AMERICA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 464 SOUTH AMERICA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 465 SOUTH AMERICA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 466 SOUTH AMERICA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 467 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 468 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 469 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 470 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 471 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 472 SOUTH AMERICA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 473 SOUTH AMERICA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 474 SOUTH AMERICA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 475 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 476 SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 477 BRAZIL PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 478 BRAZIL WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 479 BRAZIL WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 480 BRAZIL ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 481 BRAZIL SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 482 BRAZIL PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 483 BRAZIL PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 484 BRAZIL PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 485 BRAZIL PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 486 BRAZIL PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 487 BRAZIL CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 488 BRAZIL DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 489 BRAZIL DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 490 BRAZIL PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 491 BRAZIL PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 492 ARGENTINA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 493 ARGENTINA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 494 ARGENTINA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 495 ARGENTINA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 496 ARGENTINA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 497 ARGENTINA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 498 ARGENTINA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 499 ARGENTINA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 500 ARGENTINA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 501 ARGENTINA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 502 ARGENTINA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 503 ARGENTINA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 504 ARGENTINA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 505 ARGENTINA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 506 ARGENTINA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 507 REST OF SOUTH AMERICA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 508 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 509 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 510 MIDDLE EAST AND AFRICA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 511 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 512 MIDDLE EAST AND AFRICA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 513 MIDDLE EAST AND AFRICA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 514 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 515 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 516 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 517 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 518 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 519 MIDDLE EAST AND AFRICA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 520 MIDDLE EAST AND AFRICA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 521 MIDDLE EAST AND AFRICA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 522 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 523 MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 524 SOUTH AFRICA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 525 SOUTH AFRICA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 526 SOUTH AFRICA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 527 SOUTH AFRICA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 528 SOUTH AFRICA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 529 SOUTH AFRICA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 530 SOUTH AFRICA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 531 SOUTH AFRICA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 532 SOUTH AFRICA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 533 SOUTH AFRICA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 534 SOUTH AFRICA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 535 SOUTH AFRICA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 536 SOUTH AFRICA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 537 SOUTH AFRICA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 538 SOUTH AFRICA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 539 SAUDI ARABIA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 540 SAUDI ARABIA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 541 SAUDI ARABIA WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 542 SAUDI ARABIA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 543 SAUDI ARABIA SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 544 SAUDI ARABIA PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 545 SAUDI ARABIA PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 546 SAUDI ARABIA PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 547 SAUDI ARABIA PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 548 SAUDI ARABIA PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 549 SAUDI ARABIA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 550 SAUDI ARABIA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 551 SAUDI ARABIA DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 552 SAUDI ARABIA PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 553 SAUDI ARABIA PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 554 U.A.E. PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 555 U.A.E. WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 556 U.A.E. WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 557 U.A.E. ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 558 U.A.E. SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 559 U.A.E. PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 560 U.A.E. PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 561 U.A.E. PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 562 U.A.E. PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 563 U.A.E. PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 564 U.A.E. CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 565 U.A.E. DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 566 U.A.E. DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 567 U.A.E. PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 568 U.A.E. PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 569 ISRAEL PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 570 ISRAEL WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 571 ISRAEL WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 572 ISRAEL ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 573 ISRAEL SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 574 ISRAEL PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 575 ISRAEL PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 576 ISRAEL PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 577 ISRAEL PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 578 ISRAEL PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 579 ISRAEL CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 580 ISRAEL DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 581 ISRAEL DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 582 ISRAEL PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 583 ISRAEL PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 584 EGYPT PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 585 EGYPT WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 586 EGYPT WHOLE EXOME SEQUENCING IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 587 EGYPT ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 588 EGYPT SINGLE GENE TESTS IN PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 589 EGYPT PHARMACOGENETIC TESTING MARKET, BY GENE TYPE, 2021-2030 (USD MILLION)
TABLE 590 EGYPT PHARMACOGENETIC TESTING MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 591 EGYPT PHARMACOGENETIC TESTING MARKET, BY SAMPLE, 2021-2030 (USD MILLION)
TABLE 592 EGYPT PHARMACOGENETIC TESTING MARKET, BY THERAPEUTIC AREA, 2021-2030 (USD MILLION)
TABLE 593 EGYPT PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 594 EGYPT CLINICAL PRACTICE IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 595 EGYPT DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 596 EGYPT DRUG REGULATION IN PHARMACOGENETIC TESTING MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 597 EGYPT PHARMACOGENETIC TESTING MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 598 EGYPT PHARMACOGENETIC TESTING MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 599 REST OF MIDDLE EAST AND AFRICA PHARMACOGENETIC TESTING MARKET, BY TYPE, 2021-2030 (USD MILLION)
図表一覧
FIGURE 1 GLOBAL PHARMACOGENETIC TESTING MARKET: SEGMENTATION
FIGURE 2 GLOBAL PHARMACOGENETIC TESTING MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL PHARMACOGENETIC TESTING MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL PHARMACOGENETIC TESTING MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL PHARMACOGENETIC TESTING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL PHARMACOGENETIC TESTING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL PHARMACOGENETIC TESTING MARKET: DBMR MARKET POSITION GRID
FIGURE 8 GLOBAL PHARMACOGENETIC TESTING MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 GLOBAL PHARMACOGENETIC TESTING MARKET: SEGMENTATION
FIGURE 10 INCREASING ADOPTION OF PERSONALIZED MEDICINE IS DRIVING THE GROWTH OF THE GLOBAL PHARMACOGENETIC TESTING MARKET IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 11 WHOLE GENOME SEQUENCING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL PHARMACOGENETIC TESTING MARKET IN 2023 & 2030
FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL PHARMACOGENETIC TESTING MARKET
FIGURE 13 GLOBAL PHARMACOGENETIC TESTING MARKET: BY TYPE, 2022
FIGURE 14 GLOBAL PHARMACOGENETIC TESTING MARKET: BY TYPE, 2023-2030 (USD MILLION)
FIGURE 15 GLOBAL PHARMACOGENETIC TESTING MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 16 GLOBAL PHARMACOGENETIC TESTING MARKET: BY TYPE, LIFELINE CURVE
FIGURE 17 GLOBAL PHARMACOGENETIC TESTING MARKET: BY GENE TYPE, 2022
FIGURE 18 GLOBAL PHARMACOGENETIC TESTING MARKET: BY GENE TYPE, 2023-2030 (USD MILLION)
FIGURE 19 GLOBAL PHARMACOGENETIC TESTING MARKET: BY GENE TYPE, CAGR (2023-2030)
FIGURE 20 GLOBAL PHARMACOGENETIC TESTING MARKET: BY GENE TYPE, LIFELINE CURVE
FIGURE 21 GLOBAL PHARMACOGENETIC TESTING MARKET: BY DRUG TYPE, 2022
FIGURE 22 GLOBAL PHARMACOGENETIC TESTING MARKET: BY DRUG TYPE, 2023-2030 (USD MILLION)
FIGURE 23 GLOBAL PHARMACOGENETIC TESTING MARKET: BY DRUG TYPE, CAGR (2023-2030)
FIGURE 24 GLOBAL PHARMACOGENETIC TESTING MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 25 GLOBAL PHARMACOGENETIC TESTING MARKET: BY SAMPLE, 2022
FIGURE 26 GLOBAL PHARMACOGENETIC TESTING MARKET: BY SAMPLE, 2023-2030 (USD MILLION)
FIGURE 27 GLOBAL PHARMACOGENETIC TESTING MARKET: BY SAMPLE, CAGR (2023-2030)
FIGURE 28 GLOBAL PHARMACOGENETIC TESTING MARKET: BY SAMPLE, LIFELINE CURVE
FIGURE 29 GLOBAL PHARMACOGENETIC TESTING MARKET: BY THERAPEUTIC AREA, 2022
FIGURE 30 GLOBAL PHARMACOGENETIC TESTING MARKET: BY THERAPEUTIC AREA, 2023-2030 (USD MILLION)
FIGURE 31 GLOBAL PHARMACOGENETIC TESTING MARKET: BY THERAPEUTIC AREA, CAGR (2023-2030)
FIGURE 32 GLOBAL PHARMACOGENETIC TESTING MARKET: BY THERAPEUTIC AREA, LIFELINE CURVE
FIGURE 33 GLOBAL PHARMACOGENETIC TESTING MARKET: BY APPLICATION, 2022
FIGURE 34 GLOBAL PHARMACOGENETIC TESTING MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 35 GLOBAL PHARMACOGENETIC TESTING MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 36 GLOBAL PHARMACOGENETIC TESTING MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 37 GLOBAL PHARMACOGENETIC TESTING MARKET: BY END USER, 2022
FIGURE 38 GLOBAL PHARMACOGENETIC TESTING MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 39 GLOBAL PHARMACOGENETIC TESTING MARKET: BY END USER, CAGR (2023-2030)
FIGURE 40 GLOBAL PHARMACOGENETIC TESTING MARKET: BY END USER, LIFELINE CURVE
FIGURE 41 GLOBAL PHARMACOGENETIC TESTING MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 42 GLOBAL PHARMACOGENETIC TESTING MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 43 GLOBAL PHARMACOGENETIC TESTING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 44 GLOBAL PHARMACOGENETIC TESTING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 45 GLOBAL PHARMACOGENETIC TESTING MARKET: SNAPSHOT (2022)
FIGURE 46 GLOBAL PHARMACOGENETIC TESTING MARKET: COMPANY SHARE 2022 (%)
FIGURE 47 NORTH AMERICA PHARMACOGENETIC TESTING MARKET: COMPANY SHARE 2022 (%)
FIGURE 48 EUROPE PHARMACOGENETIC TESTING MARKET: COMPANY SHARE 2022 (%)
FIGURE 49 AISA-PACIFIC PHARMACOGENETIC TESTING MARKET: COMPANY SHARE 2022 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
